Jump to content
Facebook Twitter Youtube

(Lifestyle) Asofarma signs an agreement with Moderna to distribute and market its COVID vaccine in the region


Recommended Posts

Posted

Foto-2-1.jpeg

As part of the agreement reached, Asofarma will collaborate with Moderna in the management of supply contracts already in force, as well as in vaccine registration processes.

Asofarma Central America and the Caribbean, through its parent company ADIUM, and Moderna Inc. reached a collaboration agreement for the distribution and marketing in the region of Spikevax, the vaccine developed by Moderna against SARS-CoV-2.

Asofarma is a leading pharmaceutical company in the region, which develops, produces and markets innovative products in therapeutic areas such as oncology, cardiology, central nervous system, diabetes and urology, among others.

As part of the agreement reached, Asofarma will collaborate with Moderna in the management of supply contracts already in force, as well as in vaccine registration processes, support for pharmacovigilance activities, continuing medical education, government affairs, marketing, and generation of new agreements that facilitate the availability of Spikevax in the region.

“We are delighted to partner with Moderna to help patients, physicians and governments in this effort against COVID-19. Moderna is a leading company in the fight against the pandemic, and we are proud to have been chosen partners for this task, providing all our experience and regional presence”, assured Bernardo Girala, general manager of Asofarma Central America and the Caribbean. 

WhatsApp-Image-2022-02-23-at-8.06.37-AM.

"This alliance confirms our purpose of providing the po[CENSORED]tion with innovative treatments that help improve their quality of life and expand vaccination rates in the region," Girala said.

Moderna Inc., a pioneer biotechnology company in the development of messenger RNA (mRNA) therapies and vaccines, has relied on Asofarma to make possible the arrival in the region of its vaccine against COVID 19, Spikevax.

Moderna's mRNA platform is based on continuous advances in basic and applied mRNA science, delivery and manufacturing technology; which has allowed the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases.

News brought by https://www.vidayexito.net/estilo-de-vida/salud/asofarma-firma-acuerdo-con-moderna-para-distribuir-y-comercializar-su-vacuna-contra-el-covid-en-la-region/

Guest
This topic is now closed to further replies.

WHO WE ARE?

CsBlackDevil Community [www.csblackdevil.com], a virtual world from May 1, 2012, which continues to grow in the gaming world. CSBD has over 70k members in continuous expansion, coming from different parts of the world.

 

 

Important Links